Management Team

  • Scott Carmer -

    Chief Executive Officer

    Mr. Carmer brings 25 years of diverse leadership experience as a senior executive and chief commercialization officer in the biotech and pharmaceutical industry, with top-tier companies including AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. At AstraZeneca, he led the US Specialty Care Division of AstraZeneca with responsibility for the company’s portfolio of specialty care biopharmaceutical products. Prior to AstraZeneca, Mr. Carmer served as Executive Vice President, Commercial Operations of MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, most recently as Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline, where he held key roles in Global Brand Management, Business Development, Commercial Operations, Managed Care and Field Sales.

  • Han Myint - MD

    Chief Medical Officer

    Dr. Han Myint has over 20 years of experience in both academia and the biopharma industry. Before joining NexImmune, he was Vice President of Global Medical Affairs and the Myeloid Diseases Lead at Celgene. Over the past six years, his work in myeloid diseases at Celgene has contributed to a number of FDA approvals, successful launches of those products and high-impact publications. Prior to joining the biopharma industry, Dr. Myint practiced academic hematology at multiple prestigious institutions in the UK and USA, including Rush University Medical Center in Chicago. Additionally, Dr. Myint built a FACT-accredited and Center of Excellence-Designated Stem Cell Transplant Program at the University of Colorado, Denver. He has in-depth scientific knowledge, a wealth of clinical experience and expertise in hematological malignancies and stem cell transplantation. Dr. Myint graduated from the Institute of Medicine (1) in Yangon with a MBBS degree and subsequently migrated to the UK to do his postgraduate training in Internal Medicine, followed by his training in Hematology. Accordingly, he was awarded as a fellow from the Royal Colleges of Physicians and Pathologists from the UK and also from the American College of Physicians.

  • Kristi Jones -

    Chief Operating Officer

    Ms. Jones brings more than 25 years of business leadership experience in the biotech and pharmaceutical industries across strategic and operational roles. For five years prior to joining NexImmune Ms. Jones was with Astra Zeneca and its subsidiary MedImmune. From 2013-2015, Ms. Jones was Vice President of Portfolio Strategy and Management at Astra Zeneca, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the company. Prior to that she served as Vice President of Global Strategic Marketing to shape product plans and prepare MedImmune for multiple launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech, where she worked for 16 years, including Head of Immunology and Ophthalmology in Global Portfolio and Product Strategy, Endocrine and Pulmonary Franchise, and Immunology Business Unit Operations and Pipeline Planning. Ms. Jones also serves in a consulting role for various companies and organizations and serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women.

  • John Trainer -

    Chief Financial Officer

    Mr. Trainer has over 20 years of experience in various financial, transactional, strategic and commercial roles in the biopharma industry. Before joining NexImmune, he was Vice President and Head of Partnering and Strategy for MedImmune, the biologics R&D unit of the global pharmaceutical company AstraZeneca. Previous to that role, Mr. Trainer was Vice President, Corporate Development for AstraZeneca as well as the global commercial leader for AstraZeneca’s infection, neuroscience and gastrointestinal therapeutic areas. In these roles he has led multiple significant transactions, including spin-outs and financings, divestments, collaborations and in-licenses as well as managing P&L performance. Mr. Trainer also served in Board roles on AstraZeneca investments and continues to work as an advisor to life science companies. Before joining MedImmune / AstraZeneca, Mr. Trainer was as a strategy consultant at Monitor Group, where he worked in healthcare and other industries on various strategic questions including M&A strategy. Mr. Trainer received his MBA from Harvard Business School and his AB from Harvard College.

  • Daniel Bednárik, PhD -

    Senior Vice President, Molecular Engineering & Protein Design

    Dr. Bednárik has over 30 years experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer.  Prior to that, Dr. Bednárik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases.  Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednárik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at The Johns Hopkins University Oncology Center.

  • Mathias Oelke, PhD -

    Senior Vice President, Preclinical Immunotherapy and Head of Cell Biology

    Dr. Oelke is a scientific co-founder of NexImmune and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. He is also an expert in cellular immunology and T cell research. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing interest developing methods for antigen-specific stimulation of T cells for therapeutic use. He has numerous peer-reviewed publications and is a co-inventor on more than 15 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Prior to joining NexImmune in 2014, Dr. Oelke was, from 2003-2014, on the faculty at Johns Hopkins University, where he still holds an Adjunct Professorship, in the Department of Pathology. Earlier in his career Dr. Oelke who is a chemist by training, received his PhD. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in therapy.

  • Alex Matschiner, MS ChE -

    Vice President, Protein Process Development

    Alex Matschiner is a seasoned biotech industry professional with over 20 years of experience spanning start-ups through large companies, with previous roles in business operations, process development, scale-up, tech-transfer, and cGMP manufacturing; bioprocess engineering and cGMP facility design/build, start-up and validation; and project management. Prior to joining NexImmune, Alex was a consultant for multiple local biotech companies focused on process development and engineering and previously served as COO at BioFactura. He also held a Senior Scientist role in MS&T at MedImmune/Astrazeneca, and was a Senior Manager at Human Genome Sciences in different roles including Project Management, Manufacturing, and Process Engineering.

Board of Directors

  • Sol J. Barer, PhD -

    Chairman

    Dr. Barer is a founder and former Chairman, President, COO and CEO of Celgene (NASDAQ: CELG). He brings more than 30 years of experience in the biotechnology industry to the NexImmune Board of Directors. Dr. Barer currently serves as Board Chair for Teva Pharmaceuticals (NYSE: TEVA), Centrexion Therapeutics (NASDAQ: CNTX), and Aevi Genomic Medicine (NASDAQ: GNMX). He is also lead director for Contrafect Corp. (NASDAQ: CFRX) and a member of the Board of Directors for 3DBio Therapeutics. Dr. Barer is also the Founding Chair of the Hackensack Meridian Health Center for Discovery & Innovation and is a co-founder of Barer & Son Capital, an investment fund focused on capitalizing early stage breakthrough biotechnology companies.

  • Scott Carmer -

    Chief Executive Officer

    Mr. Carmer brings 25 years of diverse leadership experience as a senior executive and chief commercialization officer in the biotech and pharmaceutical industry, with top-tier companies including AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. At AstraZeneca, he led the US Specialty Care Division of AstraZeneca with responsibility for the company’s portfolio of specialty care biopharmaceutical products. Prior to AstraZeneca, Mr. Carmer served as Executive Vice President, Commercial Operations of MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, most recently as Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline, where he held key roles in Global Brand Management, Business Development, Commercial Operations, Managed Care and Field Sales.

  • Alan S. Roemer, MBA, MPH

    Alan Roemer is an entrepreneurial life sciences executive and board member who launched two biotechnology companies, raised over $1.5 billion in private and public capital, and consummated three IPOs. His senior leadership experience in development stage companies includes finance, accounting, operations & administration, business development, human resources, legal, information technology, facilities, corporate communications, and investor relations. Mr. Roemer was a founding leadership team member of Roivant Sciences, and he served in various senior management roles responsible for Finance & Operations and Corporate Development from Roivant’s inception in May 2014 through August 2019. He also simultaneously served as Chief Financial Officer of Axovant Sciences, a Roivant subsidiary, from the Axovant’s inception in October 2014 through August 2015. Prior to launching Roivant, Mr. Roemer was a Managing Director of the Trout Group, and he previously served as Chief Financial Officer & Treasurer of Zelos Therapeutics. From 1999 to 2008, Mr. Roemer was the first full-time management team member and a Vice President of Pharmasset (acquired by Gilead). Mr. Roemer is the Chair of the Audit Committee and former Chairman of the Board of NexImmune. He also serves as a Trustee of the Helene Fuld College of Nursing and a Management Committee Member of DC Brau Brewing.

  • Tim Bertram, PhD

    Chief Executive Officer of inRegen, a multi-national privately owned clinical-stage cellular therapeutics company focusing on treatment of chronic renal disease. Tim also serves as CEO of Twin City Bio, a USA-based CDMO focusing on the manufacturing and Development of cell-based therapeutics. As a Director for multiple biotechnology companies he brings over 35 years of medicine development leadership to public and private companies. Previously, CEO of RegenMed Therapeutics, after serving as President of Research and Development where we brought four cell-based therapeutic products from discovery through Phase II clinical development. Tim was a senior executive at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Corporate Research were his career focused on taking molecular entities from research through clinical development and registration. These development efforts lead to the commercialization of 8 medical products that are changing lives around the world. Tim started his professional career on faculty at the University of Illinois and as a visiting scientist at the National Institutes of Health.

  • Paul D'Angio, RPH, MSJ

    Mr. D’Angio is an advisor to several biotechnology and pharmaceutical companies and has been in the pharmaceutical industry for more than 30 years, with experience in commercial manufacturing, drug product development, risk management operations and investigational materials supply. From 1998 to 2016 he served as Senior Vice President, Global Head of Technical Operations at Celgene Corporation where he gained extensive cross-functional and technical leadership experience in building and operating a global pharmaceutical manufacturing and supply chain organization. He provided direct leadership in establishing global commercial readiness standards and practices at Celgene, resulting in a number of timely CMC filing and rapid product launches. Mr. D’Angio has a particular commitment to operational excellence and expertise in the management of highly technical cross-functional international teams focused on asset development through filing and commercialization. He has also built teams with long standing and industry leading employee engagement metrics. Earlier in his career, Mr. D’Angio served for 13 years in the manufacturing group at Novartis.

  • Zhengbin (Bing) Yao, PhD

    Dr. Yao is the Chief Executive Officer of Viela Bio. Formerly, he was the Senior Vice President, R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune. Bing was also Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca. Bing is an accomplished executive and scientist with more than 20 years of experience in the biotechnology and pharmaceutical industry. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Prior to joining MedImmune, Dr. Yao led the project team leaders (PTL) group for immunology, neurosciences, virology and metabolism for Genentech and prior to that served as Vice President of Research and Corporate Officer for Tanox before it was acquired by Genentech. Earlier in his career Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer reviewed publications and holds over 20 patents and patent applications.

  • Tony Yao, MD, PhD

    Dr. Yao is a portfolio manager at Arrowmark Partners. Previously, Tony began his investment career in 2002 at Janus Capital Group, where he was focused on making investments in biotechnology, devices, and diagnostic companies at all stages of development. Later, he was assistant portfolio manager on the Janus World Wide fund. He joined Arrowmark Partners in 2012, where he leads their healthcare team and manages the healthcare portfolio. Dr. Yao received an M.D. and Ph.D. (Immunology) from Stanford University.

Advisors

  • Miguel-Angel Perales, MD

    Dr. Perales is the Deputy Chief of the Adult Bone Marrow Transplantation Service and Director of the Adult Bone Marrow Transplant Fellowship Program at Memorial Sloan Kettering Cancer Center in New York, as well as an Associate Professor of Medicine at Weill Cornell Medical College. He is an internationally recognized leader in the field of hematopoietic stem cell transplantation, serving as a current member of the Board of Directors of Be The Match (National Marrow Donor Program - NMDP) and the American Society of Blood and Marrow Transplantation (ASBMT), where he serves as Secretary and member of the executive committee. He has also held leadership positions and been extensively involved in activities of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN). His research focuses on clinical and translational investigations of immune-based therapies in patients with cancer. Dr. Perales received his MD from the Free University of Brussels, and completed postdoctoral training at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center.

  • Paul Richardson, MD

    After comprehensive training and certification in internal medicine, hematology and medical oncology, as well as acquiring additional expertise in cancer pharmacology and transplant at Dana Farber Cancer Institute from 1994 onwards, Dr. Richardson joined the Division of Hematologic Oncology and the Jerome Lipper Multiple Myeloma Center in December, 1999. He was appointed Clinical Director of the Myeloma Center in January, 2001 and has since led several novel, biologically derived translational efforts in multiple myeloma under the overall direction and mentorship of Kenneth Anderson, MD. These have been focused in the clinical study of new drugs in the Phase 1, 2, and 3 settings as principal investigator and first author of derived manuscripts.

    Currently, he is leading multiple efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma, an area of primary interest to him. He also serves as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.

  • Jonathan Schneck, MD, PhD

    Dr. Jonathan Schneck is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Schneck received his undergraduate degree from Yeshiva University. He earned his M.D.-Ph.D. in immunology from the Albert Einstein College of Medicine. After completing his degree, he trained in pediatrics at the Children's Hospital National Medical Center in Washington, D.C. From there he worked on the medical staff of the National Institute of Allergy and Immunology at the NIH in Bethesda, and did his postdoctoral training at the Laboratory of Immunology. He joined the Johns Hopkins faculty in 1990 as a junior faculty member. His team pioneered the development of artificial white blood cells, called artificial antigen-presenting cells (aAPCs), which show promise in training animals' immune systems to fight diseases such as cancer. Dr. Schneck was the PI of a research project funded by a $10.3 million NIH grant—the largest basic immunology grant ever received by Johns Hopkins.His research focuses on T cell immunology.

  • Juan Varela, MD, PhD

    Dr Juan Carlos Varela obtained his MD, PhD from Medical University of South Carolina in 2010. He completed his residency training in internal medicine at the Osler medical training program at Johns Hopkins Hospital, followed by fellowship training in hematology at the Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. Dr. Varela’s clinical interests include novel immune therapies for hematological malignancies and bone marrow transplantation, treatments for leukemia, lymphoma and multiple myeloma. He is the principal investigator for numerous national clinical trials. Dr. Varela is passionate about providing support to his patient and their families and caregivers. His personal and professional philosophy is to treat the patient, not just the disease.